The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Various cyclin-dependent kinase (Cdk) complexes have been implicated in the regulation of transcription. In this study, we identified a 70-kDa Cyclin K (CycK) that binds Cdk12 and Cdk13 to form two different complexes (CycK/Cdk12 or CycK/Cdk13) in human cells. The CycK/Cdk12 complex regulates phosphorylation of Ser2 in the C-terminal domain of RNA polymerase II and expression of a small subset of human genes, as revealed in expression microarrays. Depletion of CycK/Cdk12 results in decreased expression of predominantly long genes with high numbers of exons. The most prominent group of down-regulated genes are the DNA damage response genes, including the critical regulators of genomic stability: BRCA1 (breast and ovarian cancer type 1 susceptibility protein 1), ATR (ataxia telangiectasia and Rad3-related), FANCI, and FANCD2. We show that CycK/Cdk12, rather than CycK/Cdk13, is necessary for their expression. Nuclear run-on assays and chromatin immunoprecipitations with RNA polymerase II on the BRCA1 and FANCI genes suggest a transcriptional defect in the absence of CycK/Cdk12. Consistent with these findings, cells without CycK/Cdk12 induce spontaneous DNA damage and are sensitive to a variety of DNA damage agents. We conclude that through regulation of expression of DNA damage response genes, CycK/Cdk12 protects cells from genomic instability. The essential role of CycK for organisms in vivo is further supported by the result that genetic inactivation of CycK in mice causes early embryonic lethality.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Micro3 showed similarities to HM_3, HM_4 phenotype but also expressed APOE, apoptosis associated genes XAF1, YWHAB, YWHAG, YWHAE encoding 14–3-3 protein subunits, cell-cycle and cell division control genes CDK12, MIS18BP1, TAF1D, BOD1L1 and CCAR1 [6, 30, 67].”
From Characterisation of premature cell senescence in Alzheimer's disease using single nuclear transcriptomics (2024) · cites this paper as [6]
In the citing paper
“To execute their functions, CDK12 and CDK13 form two separate complexes with CCNK (Blazek et al., 2011; Cheng et al., 2012).”
From Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation (2020) · cites this paper as Blazek et al., 2011
In the citing paper
“CDK12 inactivation is known to cause reduced POLII elongation and premature polyadenylation of select genes enriched in the DNA damage response pathway, resulting in a BRCAness phenotype (Blazek et al., 2011; Dubbury et al., 2018; Johnson et al., 2016).”
From Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation (2020) · cites this paper as Blazek et al., 2011
In the citing paper
“CDK12 forms a complex with CCNK to act as a transcriptional regulator of genes critically involved in DDR pathways (Blazek et al., 2011;Krajewska et al., 2019).”
From Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer (2021) · cites this paper as Blazek et al., 2011
Citations
Cites
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
The DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092 · cited 4×
“DDR operates through a large network of proteins; however, some proteins lie at the core of DDR mechanisms and regulate responses to several types of lesions (Matsuoka et al. 2007; Jackson and Bartek 2009; Ciccia and Elledge 2010).”
BackgroundInfluentialThe DNA Damage Response: Making It Safe to Play with Knives
Ciccia, A., & Elledge, S. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.019 · Cited by 4,368
ATM and ATR Substrate Analysis Reveals Extensive Protein Networks Responsive to DNA Damage
Matsuoka, S., Ballif, B. A., Smogorzewska, A., McDonald, E. R., Hurov, K. E., Luo, J., Bakalarski, C. E., Zhao, Z., Solimini, N., Lerenthal, Y., et al. (2007) · Science · doi:10.1126/science.1140321 · Cited by 3,075 · cited 2×
“DDR operates through a large network of proteins; however, some proteins lie at the core of DDR mechanisms and regulate responses to several types of lesions (Matsuoka et al. 2007; Jackson and Bartek 2009; Ciccia and Elledge 2010).”
BackgroundThe DNA Damage Response: Ten Years After
Harper, J. W., & Elledge, S. J. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.11.015 · Cited by 1,705
Bonner, W. M., Redon, C. E., Dickey, J. S., Nakamura, A. J., Sedelnikova, O. A., Solier, S., & Pommier, Y. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2523 · Cited by 1,623 · cited 2×
“DNA double-stranded breaks (DSBs) and DNA interstrand cross-links (ICLs) are among the most severe DNA lesions (Harper and Elledge 2007; Bonner et al. 2008; Jackson and Bartek 2009; Moldovan and D’Andrea 2009).”
Backgroundc-Myc Regulates Transcriptional Pause Release
Rahl, P. B., Lin, C. Y., Seila, A. C., Flynn, R. A., McCuine, S., Burge, C. B., Sharp, P. A., & Young, R. A. (2010) · Cell · doi:10.1016/j.cell.2010.03.030 · Cited by 1,279 · cited 1×
“P-TEFb is considered to be the major Ser2 kinase and was implicated in the regulation of transcriptional elongation of most, if not all, protein-coding genes (Chao et al. 2000; Nechaev and Adelman 2008; Rahl et al. 2010).”
BackgroundControlling the elongation phase of transcription with P-TEFb
Peterlin, B. M., & Price, D. H. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.06.014 · Cited by 1,144 · cited 3×
“Phosphorylation of serine at position 2 (Ser2) is thought to be responsible for productive transcriptional elongation and synthesis of full-length mature mRNA (Peterlin and Price 2006; Bres et al. 2008).”
BackgroundSelf-citationRecruitment of P-TEFb for Stimulation of Transcriptional Elongation by the Bromodomain Protein Brd4
Yang, Z., Yik, J. H. N., Chen, R., He, N., Jang, M. K., Ozato, K., & Zhou, Q. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.029 · Cited by 1,138 · cited 13×
“To determine how depletion of P-TEFb and the CycK/Cdk12 complex affects BRCA1 protein levels and global phosphorylation of Ser2, we knocked down both cyclin subunits of P-TEFb and the CycK/Cdk12 complex (Fig.”
BackgroundInfluentialiCLIP reveals the function of hnRNP particles in splicing at individual nucleotide resolution
König, J., Zarnack, K., Rot, G., Curk, T., Kayikci, M., Zupan, B., Turner, D. J., Luscombe, N. M., & Ule, J. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1838 · Cited by 1,126 · cited 1×
“CEL files were first analyzed with version 3 of ASPIRE software (Konig et al. 2010).”
MethodSelf-citation
Research works printed but not linked: 1
- 10.1038/nature10166 · DOI · Paper page
Cited by
Items 101–200 of 542
Niu, T., Li, K., Li, J., Zhou, Z., Hong, J.-E., Chen, X., Dong, X., He, Q., Cao, J., Yang, B., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114012 · Cited by 99
Targeting cyclin-dependent kinases in anti-neoplastic therapy
Bruyère, C., & Meijer, L. (2013) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2013.08.004 · Cited by 95
The emerging roles of CDK12 in tumorigenesis
Paculová, H., & Kohoutek, J. (2017) · Cell Division · doi:10.1186/s13008-017-0033-x · Cited by 95
“CDK12 is necessary for expression of DDR genes and it is essential for HR mediated DNA repair [12, 50].”
Self-citationBartholomeeusen, K., Fujinaga, K., Xiang, Y., & Peterlin, B. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.464834 · Cited by 95
“were as follows: For GAPDH normalization, primers are described in (28).”
MethodSelf-citationTranscriptional elongation control in developmental gene expression, aging, and disease
Aoi, Y., & Shilatifard, A. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.10.004 · Cited by 91
CDK12 phosphorylates 4E-BP1 to enable mTORC1-dependent translation and mitotic genome stability
Choi, S. H., Martinez, T. F., Kim, S., Donaldson, C. J., Shokhirev, M. N., Saghatelian, A., & Jones, K. A. (2019) · Genes & Development · doi:10.1101/gad.322339.118 · Cited by 95
“Based on the observation that CDK12 targets DNA repair genes (Blazek et al. 2011), we wondered whether it is also needed for the p53-regulated response to DNA damage (Matt and Hofmann 2016).”
InfluentialTargeting DNA Damage Response in Prostate and Breast Cancer
Wengner, A. M., Scholz, A., & Haendler, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218273 · Cited by 89
PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”
Boussios, S., Karathanasi, A., Cooke, D., Neille, C., Sadauskaite, A., Moschetta, M., Zakynthinakis-Kyriakou, N., & Pavlidis, N. A. (2019) · Diagnostics · doi:10.3390/diagnostics9020055 · Cited by 81
“The knockdown of cyclin-dependent kinase 12 (CDK12) resulted in concomitant downregulation of DNA repair proteins, and consequently the development of a “BRCAness” phenotype [130].”
BackgroundCDK12: A Potent Target and Biomarker for Human Cancer Therapy
Liang, S., Hu, L., Wu, Z., Chen, Z., Liu, S., Xu, X., & Qian, A. (2020) · Cells · doi:10.3390/cells9061483 · Cited by 82
“Interestingly, RNAP II transcription is not globally impaired in cells without CDK12/cyclin K complex [13].”
BackgroundInfluentialSokol, E. S., Pavlick, D. C., Frampton, G. M., Ross, J. S., Miller, V. A., Ali, S. M., Lotan, T. L., Pardoll, D. M., Chung, J., & Antonarakis, E. S. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0214 · Cited by 87
“of homologous recombination repair genes [6].”
Patel, M. A., Nowsheen, S., Maraboyina, S., & Xia, F. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00390-7 · Cited by 80
Cyclin K regulates prereplicative complex assembly to promote mammalian cell proliferation
Lei, T., Zhang, P., Zhang, X., Xiao, X., Zhang, J., Qiu, T., Dai, Q., Zhang, Y., Min, L., Li, Q., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04258-w · Cited by 81
Giuliani, V., Miller, M. A., Liu, C.-Y., Hartono, S. R., Class, C. A., Bristow, C. A., Suzuki, É., Sanz, L. A., Gao, G., Gay, J. P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24798-y · Cited by 81
Members of the Undiagnosed Diseases Network, Bostwick, B. L., McLean, S., Posey, J. E., Streff, H. E., Gripp, K. W., Blesson, A., Powell-Hamilton, N., Tusi, J., Stevenson, D. A., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0463-8 · Cited by 74
“CDK12 and CDK13 are thought to have evolved by duplication of a common gene ancestor; however, both kinases appear to operate in separate complexes in mammalian cells [6, 7].”
BackgroundIto, M., Tanaka, T., Toita, A., Uchiyama, N., Kokubo, H., Morishita, N., Klein, M. G., Zou, H., Murakami, M., Kondo, M., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00683 · Cited by 73
AlHilli, M. M., Becker, M. A., Weroha, S. J., Flatten, K. S., Hurley, R. M., Harrell, M. I., Oberg, A. L., Maurer, M. J., Hawthorne, K. M., Hou, X., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.08.328 · Cited by 73
Jarman, P. J., Noakes, F. F., Fairbanks, S. D., Smitten, K. L., Griffiths, I. K., Saeed, H. K., Thomas, J. A., & Smythe, C. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b09999 · Cited by 73
Regulation of expression of human RNA polymerase II-transcribed snRNA genes
Guiro, J., & Murphy, S. (2017) · Open Biology · doi:10.1098/rsob.170073 · Cited by 87
Kanakkanthara, A., Kurmi, K., Ekstrom, T. L., Hou, X., Purfeerst, E. R., Heinzen, E. P., Correia, C., Huntoon, C. J., O’Brien, D. R., Hendrickson, A. E. W., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1405 · Cited by 76
“In a smaller subset of HGSOCs, HR defects reflect transcriptional repression of BRCA1 resulting from hypermethylation of the BRCA1 promoter or mutational inactivation of cyclin dependent kinase 12 (CDK12), which regulates transcription of BRCA1 and other genes involved in DNA repair (2,3).”
BackgroundResultThe emerging picture of CDK9/P-TEFb: more than 20 years of advances since PITALRE
Paparidis, N. F. D. S., Durvale, M. D. C., & Canduri, F. (2016) · Molecular BioSystems · doi:10.1039/c6mb00387g · Cited by 83
Naidoo, K., Wai, P. T., Maguire, S. L., Daley, F. M., Haider, S., Kriplani, D., Campbell, J., Mirza, H., Grigoriadis, A. E., Tutt, A. N. J., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0760 · Cited by 80
“highly expressed (7-8), however, revealed a significant association between CDK12 amplification and increased CDK12 protein expression with 12/16 (75%) amplified”
CDK12 and PAK2 as novel therapeutic targets for human gastric cancer
Liu, H., Shin, S. H., Chen, H., Liu, T., Li, Z., Hu, Y., Liu, F., Zhang, C., Kim, D. J., Liu, K., et al. (2020) · Theranostics · doi:10.7150/thno.46137 · Cited by 71
“CDK12 is known to phosphorylate the large subunit of RNA polymerase II (POLR2A) at the C-terminal domain (CTD), as well as translation factor 4E-BP1 [7, 10, 11], thereby regulating Ivyspring”
BackgroundKey Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets
Khamidullina, A. I., Abramenko, Y. E., Bruter, A. V., & Tatarskiy, V. V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021263 · Cited by 81
“CDK12/13 are involved in transcriptional regulation of a number of DDR genes such as BRCA1 , ATR and FANC1 [243].”
BackgroundCDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells
Delehouzé, C., Godl, K., Loaëc, N., Bruyère, C., Desban, N., Oumata, N., Galons, H., Roumeliotis, T. I., Giannopoulou, E. G., Grenet, J., et al. (2014) · Oncogene · doi:10.1038/onc.2013.513 · Cited by 69
Regulation of RAD51 at the Transcriptional and Functional Levels: What Prospects for Cancer Therapy?
Orhan, E., Velázquez, C., Tabet, I., Sardet, C., & Theillet, C. G. (2021) · Cancers · doi:10.3390/cancers13122930 · Cited by 76
“CDK13, which has strong sequence homology with CDK12, has been predicted to share a similar role in pre-mRNA processing [36].”
BackgroundOncogenic CDK13 mutations impede nuclear RNA surveillance
Insco, M. L., Abraham, B. J., Dubbury, S. J., Kaltheuner, I. H., Dust, S., Wu, C., Chen, K. Y., Liu, D., Bellaousov, S., Cox, A. M., et al. (2023) · Science · doi:10.1126/science.abn7625 · Cited by 74
“RNA signature No loss of DNA repair gene expression Loss of DNA repair gene expression (7, 8, 40, 66) .”
BackgroundMechanisms of PARP1 inhibitor resistance and their implications for cancer treatment
Jackson, L. M., & Moldovan, G. (2022) · NAR Cancer · doi:10.1093/narcan/zcac042 · Cited by 78
PARP mediated DNA damage response, genomic stability and immune responses
Zong, C., Zhu, T., He, J., Huang, R., Jia, R., & Shen, J. (2022) · International Journal of Cancer · doi:10.1002/ijc.33918 · Cited by 74
Lost in Transcription: Molecular Mechanisms that Control HIV Latency
Taube, R., & Peterlin, B. M. (2013) · Viruses · doi:10.3390/v5030902 · Cited by 68
“A third cyclin, CycK, was also thought to partner with CDK9, but was demonstrated later to bind to CDK12 and CDK13 to regulate DNA damage response genes [50,51,52,53].”
BackgroundSelf-citationCDK11 in TREX/THOC Regulates HIV mRNA 3′ End Processing
Pak, V., Eifler, T., Jäger, S., Krogan, N. J., Fujinaga, K., & Peterlin, B. M. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2015.10.012 · Cited by 71
“Knock down of CDK12 was an important control as it also affects 3’ end processing via the EJC, but mostly of longer genes with many exons and introns (Blazek et al., 2011).”
BackgroundSelf-citationJiang, B., Jiang, J., Kaltheuner, I. H., Iniguez, A. B., Anand, K., Ferguson, F. M., Ficarro, S. B., Seong, B. K. A., Greifenberg, A. K., Dust, S., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113481 · Cited by 64
Cyclin-Dependent Kinase 12 Increases 3′ End Processing of Growth Factor-Induced c-FOS Transcripts
Eifler, T. T., Shao, W., Bartholomeeusen, K., Fujinaga, K., Jäger, S., Johnson, J. R., Luo, Z., Krogan, N. J., & Peterlin, B. M. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.01157-14 · Cited by 63
“CDK12 exists as a CycK: CDK12 heterodimer in vivo (24, 26, 27).”
BackgroundInfluentialSelf-citationGenome-wide identification of loci associated with growth in rainbow trout
Ali, A., Al-Tobasei, R., Lourenco, D. A. L., Leeds, T. D., Kenney, B., & Salem, M. (2020) · BMC Genomics · doi:10.1186/s12864-020-6617-x · Cited by 74
Janysek, D. C., Kim, J. S., Duijf, P. H. G., & Dray, E. V. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101012 · Cited by 73
PNUTS/PP1 Regulates RNAPII-Mediated Gene Expression and Is Necessary for Developmental Growth
Ciurciu, A., Duncalf, L., Jonchère, V., Lansdale, N., Vasieva, O., Glenday, P., Rudenko, A., Vissi, E., Cobbe, N., Alphey, L., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003885 · Cited by 69
“gene-specific patterns of expression [12,13].”
Shen, S., Dean, D. C., Yu, Z., & Duan, Z. (2019) · Hepatology Research · doi:10.1111/hepr.13353 · Cited by 62
Cyclin K-containing Kinase Complexes Maintain Self-renewal in Murine Embryonic Stem Cells
Dai, Q., Lei, T., Zhao, C., Zhong, J., Tang, Y.-Z., Chen, B., Yang, J., Li, C., Wang, S., Song, X., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.321760 · Cited by 65
“Interestingly, they also showed that CDK12 may regulate expression of a subset of genes involved in DNA damage response (28).”
BackgroundResultInfluentialStructure‐Based Design of Selective Noncovalent CDK12 Inhibitors
Johannes, J. W., Denz, C. R., Su, N., Wu, A. J., Impastato, A. C., Mlynarski, S. N., Varnes, J. G., Prince, D. B., Cidado, J. R., Gao, N., et al. (2017) · ChemMedChem · doi:10.1002/cmdc.201700695 · Cited by 62
Synthetic Lethality through the Lens of Medicinal Chemistry
Myers, S. H., Ortega, J. A., & Cavalli, A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00766 · Cited by 65
The Promise and Current Status of CDK12/13 Inhibition for the Treatment of Cancer
Tadesse, S., Duckett, D. R., & Monastyrskyi, A. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0240 · Cited by 69
Cyclins and cyclin-dependent kinases: from biology to tumorigenesis and therapeutic opportunities
Zabihi, M., Lotfi, R., Yousefi, A., & Bashash, D. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04135-6 · Cited by 67
Human CDK18 promotes replication stress signaling and genome stability
Barone, G., Staples, C. J., Ganesh, A., Patterson, K. W., Bryne, D. P., Myers, K. N., Patil, A. A., Eyers, C. E., Maslen, S., Skehel, J. M., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw615 · Cited by 59
“In doing so, CDK12/Cyclin K therefore modulates the transcriptional activity of RNA Polymerase II (POLII) toward a select panel of DNA damage genes including ATR, CHK1 and FANCD2 (52).”
InfluentialSansó, M., Lee, K. M., Viladevall, L., Jacques, P., Pagé, V., Nagy, S., Racine, A., Amour, C. V. S., Zhang, C., Shokat, K. M., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002822 · Cited by 66
“Although Ctk1 was proposed to be a yeastspecific P-TEFb paralog [41], putative orthologs of Ctk1 have recently been identified in human and Drosophila cells [42,43], suggesting faithful conservation of the entire CTD kinase network.”
BackgroundHsin, J.-P., Xiang, K., & Manley, J. L. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00181-14 · Cited by 68
“, CDK12 and -13 (10, 11), which may not be inhibited by the CDK9 inhibitors (60), and thus could perhaps partially compensate for CDK9.”
BackgroundLiu, P., Xiang, Y., Fujinaga, K., Bartholomeeusen, K., Nilson, K. A., Price, D. H., & Peterlin, B. M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.539015 · Cited by 64
“For GAPDH normalization, primers were as described previously (12).”
MethodSelf-citationLiu, Y., Hao, M., Leggett, A. L., Gao, Y., Ficarro, S. B., Che, J., He, Z., Olson, C. M., Marto, J. A., Kwiatkowski, N. P., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01929 · Cited by 55
Bartkowiak, B., & Greenleaf, A. L. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.612226 · Cited by 53
“In agreement with this functional annotation, the presence of RS domains in the CDK12 N terminus, and the CDK12 localization to nuclear speckles (8, 10) we find serine/arginine repetitive matrix protein 1 and 2, and many SR Splicing Factors (SRSF1, 3, 4, 5, 6, 7, 8, 9, and 10) coprecipitating with CDK12.”
BackgroundMethodInfluentialRole and therapeutic potential of CDK12 in human cancers
Chilà, R., Guffanti, F., & Damia, G. L. M. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.09.003 · Cited by 54
Key Players in HIV-1 Transcriptional Regulation: Targets for a Functional Cure
Mori, L., & Valente, S. T. (2020) · Viruses · doi:10.3390/v12050529 · Cited by 61
“Depletion of CDK12/13 results in a reduced expression of long cellular genes with multiple exons [200], as well as defects in RNA processing [152].”
BackgroundKaragiannakos, A., Adamaki, M., Tsintarakis, A., Vojtěšek, B., Fåhræus, R., Zoumpourlis, V. C., & Karakostis, K. (2022) · Cancers · doi:10.3390/cancers14030664 · Cited by 64
Splicing inhibition decreases phosphorylation level of Ser2 in Pol II CTD
Koga, M., Hayashi, M., & Kaida, D. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv740 · Cited by 63
“How do cells regulate the Ser2 phosphorylation level depending on splicing activity? Ser2 phosphorylation is carried out by kinases P-TEFb and the CDK12/CycK complex (7,8,11,12).”
BackgroundHjorth-Jensen, K., Maya‐Mendoza, A., Dalgaard, N., Sigurðsson, J. O., Bártek, J., Iglesias‐Gato, D., Olsen, J. V., & Flores‐Morales, A. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky719 · Cited by 55
“The role of the general transcription and pre-mRNA processing machinery in promoting genome stability has been emphasized by recent studies detailing how interference with core processes such as transcriptional elongation (34), splicing (35,36), or mRNA export (37) appears to selectively affect transcripts encoding re…”
BackgroundPharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use
Abbotts, R., Dellomo, A. J., & Rassool, F. V. (2022) · Cancers · doi:10.3390/cancers14112640 · Cited by 59
“Notably, several DNA damage response genes are susceptible to PCPA due to their relatively long length and high number of cryptic polyadenylation sites, including BRCA1, ATR, and the FA genes FANCI and FANCD2, and hence CDK12 has been ascribed a role in the promotion of HR activity and genomic stability [95].”
BackgroundCesari, E., Ciucci, A., Pieraccioli, M., Caggiano, C., Nero, C., Bonvissuto, D., Sillano, F., Buttarelli, M., Piermattei, A., Loverro, M., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02682-5 · Cited by 64
“While this activity is likely to occur genome-wide, inhibition or ablation of CDK12 function was shown to prevalently affect expression of DDR genes and to cause DNA repair defects [11], hence sensitizing different types of cancer cells to PARPi [12, 13].”
BackgroundCo-transcriptional splicing and the CTD code
Custódio, N., & Carmo‐Fonseca, M. (2016) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2016.1230086 · Cited by 50
“In humans, two proteins (CDK12 and CDK13) are homologous to Drosophila CDK12 (Blazek et al., 2011).”
BackgroundInfluentialHoules, T., Boucher, J., Lavoie, G., MacLeod, G., Lin, S., Angers, S., & Roux, P. P. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01754-x · Cited by 49
“As CDK12 inhibition was previously shown to decrease the expression of many DDR genes [2], we quanti fi ed the abundance of BRCA1 , RAD51 , ATM , XRCC2 , FANCI and FANCD2 in response to two different doses of SR-4835 (30 and 100 nM).”
BackgroundLin, X., Beckers, E., Cafferty, S. M., Gansemans, Y., Szymańska, K. J., Pavani, K. C., Catani, J. P., Nieuwerburgh, F. V., Deforce, D. L. D., Sutter, P. D., et al. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00315 · Cited by 55
“, 2016) and to maintain genomic stability as Cyclin K/CDK12 complex (Blazek et al., 2011) through regulating DDR genes.”
BackgroundDNA-PK in human malignant disorders: Mechanisms and implications for pharmacological interventions
Medová, M., Medo, M., Hovhannisyan, L., Muñoz-Maldonado, C., Aebersold, D. M., & Zimmer, Y. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107617 · Cited by 50
“Apart of the impact of promoter polymorphism, among other potentialmechanisms leading to deregulated DNA-PK expression, the CDK12/ Cyclin K complex has been reported to affect genome stability through the regulation of RNA polymerase II activity, which controls the transcription of various DDR components, including BR…”
BackgroundFancy, N. N., Smith, A. M., Caramello, A., Tsartsalis, S., Davey, K., Muirhead, R. C. J., McGarry, A., Jenkyns, M. H., Schneegans, E., Chau, V., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02727-9 · Cited by 48
“Micro3 showed similarities to HM_3, HM_4 phenotype but also expressed APOE , apoptosis associated genes XAF1, YWHAB, YWHAG, YWHAE encoding 14–3-3 protein subunits, cell-cycle and cell division control genes CDK12, MIS18BP1, TAF1D, BOD1L1 and CCAR1 [6, 30, 67].”
BackgroundGadducci, A., & Guerrieri, M. E. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.04.006 · Cited by 60
New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer
Conteduca, V., Mosca, A., Brighi, N., Giorgi, U. D., & Rescigno, P. (2021) · Cells · doi:10.3390/cells10010193 · Cited by 58
“CDK12 is reportedly involved in regulating expression of several HR genes [77]; somatic defects in CDK12 are associated with a genome-wide focal tandem duplication (FTD) signature [78].”
BackgroundMurata, S., Zhang, C., Finch, N., Zhang, K., Campo, L., & Breuer, E.-K. Y. (2016) · BioMed Research International · doi:10.1155/2016/2346585 · Cited by 52
“CDK12 is a kinase that regulates cell cycle checkpoints and positively regulates BRCA1 [88].”
BackgroundOcaña, A., & Pandiella, A. (2017) · Oncotarget · doi:10.18632/oncotarget.14731 · Cited by 50
“Interestingly, CDK12 has been associated with genomic stability [48], one of the characteristics of BRCA1/2 mutated TNBCs.”
BackgroundNaro, C., Bielli, P., & Sette, C. (2021) · FEBS Journal · doi:10.1111/febs.16057 · Cited by 59
Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma
Bayles, I., Krajewska, M., Pontius, W. D., Saiakhova, A., Morrow, J. J., Bartels, C., Lu, J., Faber, Z. J., Fedorov, Y., Hong, E. S., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127718 · Cited by 46
“CDK12 has been shown to regulate the expression of DDR genes and thus facilitate genome stability (36).”
BackgroundFilippone, M. G., Gaglio, D., Bonfanti, R., Tucci, F. A., Ceccacci, E., Pennisi, R., Bonanomi, M., Jodice, G., Tillhon, M., Montani, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30375-8 · Cited by 51
CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer
Lei, H., Wang, Z., Jiang, D., Liu, F., Liu, M., Lei, X., Yang, Y., He, B., Yan, M., Huang, H. W., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04027-6 · Cited by 49
“CDK12 primarily regulates transcription elongation by phosphorylating serine-2 (S2) of the C-terminal domain (CTD) of RNA polymerase II (RNAPII) [13] and plays an essential role in DNA damage repair (DDR), especially homologous recombination (HR) [14, 15].”
BackgroundEngineering an analog-sensitive CDK12 cell line using CRISPR/Cas
Bartkowiak, B., Yan, C., & Greenleaf, A. L. (2015) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2015.07.010 · Cited by 46
Cell cycle regulation and hematologic malignancies
Dai, Y., Jin, F., Wu, W., & Kumar, S. K. (2019) · Blood Science · doi:10.1097/bs9.0000000000000009 · Cited by 48
“Interestingly, the cyclin K–CDK12 complex only regulates the expression of a small subset of genes, predominantly long genes with high exon numbers and DDR genes, including critical regulators of genomic stability, such as BRCA1, ATR, FANCI, and FANCD2.(116) Dai et al.”
BackgroundSmall Molecule CDK Inhibitors for the Therapeutic Management of Cancer
Goel, B., Tripathi, N., Bhardwaj, N., & Jain, S. K. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200516152756 · Cited by 48
Cyclin‐dependent kinases: Masters of the eukaryotic universe
Pluta, A. J., Studniarek, C., Murphy, S., & Norbury, C. J. (2023) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1816 · Cited by 57
Schecher, S., Walter, B., Falkenstein, M., Macher‐Goeppinger, S., Stenzel, P., Krümpelmann, K., Hadaschik, B. A., Perner, S., Kristiansen, G., Duensing, S. M., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30864 · Cited by 48
“showed that homozygous CycK knockout is lethal in early embryogenic development.(11) These data support the evidence that CycK plays a key role in cell development.”
BackgroundResultInfluentialTien, J. C.-Y., Luo, J., Chang, Y., Zhang, Y., Cheng, Y., Wang, X., Yang, J., Mannan, R., Mahapatra, S., Shah, P., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101758 · Cited by 52
Chen, H., Lin, G.-T., Huang, C.-K., & Fann, M. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.06.024 · Cited by 48
Li, X., Chatterjee, N., Spirohn, K., Boutros, M., & Bohmann, D. (2016) · Scientific Reports · doi:10.1038/srep21455 · Cited by 47
Aflatoxin B1 Occurrence, Detection and Toxicological Effects
Long, X.-D. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.77925 · Cited by 49
Šmerdová, L., Svobodová, J., Kabátková, M., Kohoutek, J., Blažek, D., Machala, M., & Vondráček, J. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu190 · Cited by 43
“The chromatin immunoprecipitation (ChIP) assays were performed as described previously (25).”
MethodSelf-citationConnection between Tumor Suppressor BRCA1 and PTEN in Damaged DNA Repair
Minami, A., Nakanishi, A., Ogura, Y., Kitagishi, Y., & Matsuda, S. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00318 · Cited by 56
“The BRCA1 activates the CDK inhibitor p21WAF1 and the p53 tumor suppressor protein, which regulates several genes that control cell cycle checkpoints (33, 34).”
BackgroundDNA repair defects in prostate cancer: impact for screening, prognostication and treatment
Warner, E. W., Yip, S., Chi, K. N., & Wyatt, A. W. (2018) · British Journal of Urology · doi:10.1111/bju.14576 · Cited by 42
CDK12: cellular functions and therapeutic potential of versatile player in cancer
Pilařová, K., Herudek, J., & Blažek, D. (2020) · NAR Cancer · doi:10.1093/narcan/zcaa003 · Cited by 50
“This finding, together with discoveries that CDK12 is among few recurrently mutated genes in ovarian carcinoma (4) and regulates genome stability via regulating the transcription of key DNA repair genes (5), sparked research interest in the cellular functions of CDK12.”
BackgroundInfluentialChu, Y., Yam, C., Chen, M., Chan, L.-C., Xiao, M., Wei, Y., Yamaguchi, H., Lee, P., Han, Y., Nie, L., et al. (2020) · PubMed Central · Cited by 51
Amour, C. V. S., Sansó, M., Bösken, C. A., Lee, K. M., Larochelle, S., Zhang, C., Shokat, K. M., Geyer, M., & Fisher, R. P. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06657-11 · Cited by 52
“P-TEFb was thought to generate the bulk of Ser2-P in metazoans, but that assignment was challenged by the discovery of Cdk12 and Cdk13 as Ser2 kinases recruited during elongation (3, 4).”
PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review
Ratta, R., Guida, A., Scotté, F., Neuzillet, Y., Benmaziane, A., Lebrét, T., & Beuzeboc, P. (2020) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-020-0233-3 · Cited by 41
Choi, S. H., Kim, S., & Jones, K. A. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0442-9 · Cited by 37
CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma
Houles, T., Lavoie, G., Nourreddine, S., Cheung, W., Vaillancourt-Jean, É., Guérin, C. M., Bouttier, M., Grondin, B., Lin, S., Saba-El-Leil, M. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34179-8 · Cited by 40
The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma
Liao, Y., Feng, Y., Shen, J. K., Hornicek, F. J., & Duan, Z. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9601-1 · Cited by 44
Castillo, J., Knol, J. C., Korver, C. M., Piersma, S. R., Pham, T. V., Haas, R. R. D. G., van Pelt, A. M. M., Jiménez, C. R., & Jansen, B. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra118.001278 · Cited by 44
“become active, such as the cyclin K (61, 62, 69, 70).”
BackgroundDong, B., Fan, L., Yang, B., Chen, W., Li, Y., Wu, K., Zhang, F., Dong, H., Cheng, H., Pan, J., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7663 · Cited by 43
Henry, K. L., Kellner, D., Bajrami, B., Anderson, J. E., Beyna, M., Bhisetti, G., Cameron, T. O., Capacci, A. G., Bertolotti‐Ciarlet, A., Feng, J., et al. (2018) · Science Signaling · doi:10.1126/scisignal.aam8216 · Cited by 40
“The following TaqMan probes (Thermo Fisher Scientific) were used: CDK12, Hs00212914_m1; MAP3K14 (NIK), Hs01089753_m1; NFkB2, Hs01028901_g1; RAD51, Hs00947967_m1; and ACTB (b-actin), 4352935.”
BackgroundInfluentialRegulatory Potential of the RNA Processing Machinery: Implications for Human Disease
Carey, K. T., & Wickramasinghe, V. O. (2018) · Trends in Genetics · doi:10.1016/j.tig.2017.12.012 · Cited by 42
Gupta, M., Iyer, R. V., & Fountzilas, C. K. (2019) · Cancers · doi:10.3390/cancers11121980 · Cited by 43
“Inhibition of CDK12 leads to downregulation of DDR genes [114] and reverses resistance to PARPi in breast cancer [115] and multiple myeloma in vitro [116].”
BackgroundTranscriptional cyclin-dependent kinases as the mediators of inflammation-a review
Sundar, V., Vimal, S., Mithlesh, M. S. S., Dutta, A., Tamizhselvi, R., & Manickam, V. (2020) · Gene · doi:10.1016/j.gene.2020.145200 · Cited by 42
Hurley, R. M., McGehee, C. D., Nesic, K., Correia, C., Weisskittel, T., Kelly, R. L., Venkatachalam, A., Hou, X., Pathoulas, N. M., Meng, X. W., et al. (2021) · NAR Cancer · doi:10.1093/narcan/zcab028 · Cited by 42
Jorda, R., Havlíček, L., Peřina, M., Vojáčková, V., Pospíšil, T., Djukic, S., Škerlová, J., Grúz, J., Renešová, N., Klener, P., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02184 · Cited by 41
Dixon-Clarke, S. E., Elkins, J. M., Cheng, S.-W. G., Morin, G. B., & Bullock, A. N. (2015) · Scientific Reports · doi:10.1038/srep17122 · Cited by 38
Nguyen, C. B., Reimers, M. A., Perera, C. D., Abida, W. M., Chou, J., Feng, F. Y.-C., Antonarakis, E. S., McKay, R. R., Pachynski, R. K., Zhang, J., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0400 · Cited by 50
The CDK9 Tail Determines the Reaction Pathway of Positive Transcription Elongation Factor b
Baumli, S., Hole, A. J., Wang, L.-Z., Noble, M. E. M., & Endicott, J. A. (2012) · Structure · doi:10.1016/j.str.2012.08.011 · Cited by 38
P-TEFb goes viral: The role of P-TEFb in viral infection
Zaborowska, J., Isa, N. F., & Murphy, S. (2015) · Inside the Cell · doi:10.1002/icl3.1037 · Cited by 37
“clin K associates with CDK12 and CDK13 [28].”
BackgroundZhou, C., Feng, X., Yuan, F., Ji, J., Shi, M., Yu, Y., Zhu, Z., & Zhang, J. (2018) · Cancer Management and Research · doi:10.2147/cmar.s172710 · Cited by 46
“17,18 In tumor, the activity of those genes has been correlated with resistance to platinum-containing chemotherapy.”
Phosphorylation of RNA polymerase II is independent of P-TEFb in the C. elegans germline
Bowman, E. A., Bowman, C. R., Ahn, J. H., & Kelly, W. G. (2013) · Development · doi:10.1242/dev.095778 · Cited by 38
“Cyclin K is the cyclin partner of CDK-12 in other systems (Bartkowiak et al., 2010; Blazek et al., 2011; Kohoutek and Blazek, 2012).”
BackgroundResult
Metadata
- Authors
- Blazek, D., Kohoutek, J., Bartholomeeusen, K., Johansen, E., Hulinkova, P., Luo, Z., Cimermancic, P., Ule, J., & Peterlin, B. M.
- Affiliations
- University of California, San Francisco (US)
- MRC Laboratory of Molecular Biology (GB)
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2011-10-15
- Volume
- 25
- Issue
- 20
- Pages
- 2158-2172
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- PMC
- PMC3205586
- OpenAlex
- W2123814549
- Cited by
- 522
- References
- 57
- Citations by year
- 2026: 40 · 2025: 36 · 2024: 52 · 2023: 40 · 2022: 35 · 2021: 40 · 2020: 52 · 2019: 45 · 2018: 33 · 2017: 24 · 2016: 29 · 2015: 25 · 2014: 23 · 2013: 24 · 2012: 24
- Type
- posted content
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Genes & Development (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Wellcome Trust (089701)
- Grantová Agentura České Republiky
- National Institutes of Health (GM082250)
- National Institute of General Medical Sciences (P50GM082250, IP50 GM082250)
- National Institute of Allergy and Infectious Diseases (R01AI49104, R01AI049104)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- cyclin K, CDK12, CDK13, RNA polymerase II Ser2 phosphorylation, transcriptional regulation, DNA damage response genes, genome stability, BRCA1, ATR, FANCI, FANCD2, spontaneous DNA damage, embryonic lethality
- MeSH terms
- Animals, DNA Damage, HeLa Cells, Humans, Phosphorylation, CDC2 Protein Kinase, Cyclins, Mice, Knockout, Gene Expression Regulation, Developmental, Cyclin-Dependent Kinases, Genomic Instability, Cyclin-Dependent Kinase 9, Mice, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.